• Explore /
  • Poster
  • / Second-line regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) after progression on first-line atezolizumab plus bevacizumab (Atezo-Bev): Phase 2 REGONEXT trial.

Second-line regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) after progression on first-line atezolizumab plus bevacizumab (Atezo-Bev): Phase 2 REGONEXT trial.

Abstract Poster

Authors

null

Changhoon Yoo

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Changhoon Yoo , Jaekyung Cheon , Baek-Yeol Ryoo , Min-Hee Ryu , Hyung-Don Kim , Kyu-Pyo Kim , Beodeul Kang , Hong Jae Chon , Richard S. Finn

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05134532

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 477)

DOI

10.1200/JCO.2024.42.3_suppl.477

Abstract #

477

Poster Bd #

C2

Abstract Disclosures

Similar Posters

First Author: Jaekyung Cheon

First Author: Guoliang Shao

First Author: Kazuomi Ueshima

First Author: Xiang Nong